Open AccessOne-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
Author(s) -
Thi Ha Chau Tran,
Ali Erginay,
Stéphane Verdun,
E. Fourmaux,
JeanFrançois Le Rouic,
J. Uzzan,
S. Milazzo,
S. Baillif,
Laurent Kodjikian
Publication year - 2021
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s304030
Subject(s) - medicine , aflibercept , vitrectomy , ophthalmology , visual acuity , diabetic retinopathy , ranibizumab , bevacizumab , macular edema , triamcinolone acetonide , surgery , diabetes mellitus , chemotherapy , endocrinology
To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year.